Weekday on-weekend off oral capecitabine: A phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 5, 2007, Pages 733-739

  Pentheroudakis, G ^a   Pappas, P ^a   Golfinopoulos, V ^a   Fountzilas, G ^b   Nikolaidou, M ^a   Boumba, V A ^a   Vougiouklakis, T ^a   Nikiforidis, L ^a   Tzamakou, E ^a   Siarabi, O ^a   Marselos, M ^a   Pavlidis, N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Capecitabine; Fluoropyrimidine; Pharmacokinetics; Phase I trials

Indexed keywords

CAPECITABINE; DRUG METABOLITE; FLUOROPYRIMIDINE;

ABDOMINAL CRAMP; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BONE METASTASIS; BREAST CANCER; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PERITONEUM METASTASIS; PHASE 1 CLINICAL TRIAL; PLEURA METASTASIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIMULATION; SKIN TOXICITY; SOLID TUMOR; STANDARD; STOMACH CANCER; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PRODRUGS;

EID: 34547850493     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0419-6     Document Type: Article

References (23)

1. Presant CA, Wolf W, Albright MJ, Servis KL, Ring R et al. (1990) Human tumour fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 8:1868-1873
2. Peters GJ, Lankelma J, Kok RM, Noordhuis P, van Groeningen CJ et al. (1993) Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumours as compared with plasma. Cancer Chemother Pharmacol 31:269-276
3. Thomas CM, Zalcberg JR (1998) 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 25:887-895
4. Meta-Analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308
5. De Gramont A, Bosset JF, Milan C et al. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808-815
6. Pentheroudakis G, Twelves C (2002) The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 22:3589-3596
7. Van Cutsem E, Findlay M, Osterwalder B et al. (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18:1337-1345
8. Ishitsuka H (2000) Capecitabine: preclinical pharmacology studies. Invest New Drugs 18:343-354
9. Evans TR, Pentheroudakis G, Paul J et al. (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 13:1469-1478
10. Anderson D, Kerr DJ, Blesing C et al. (1997) Simultaneous gas chromatographic-mass spectrophotometric determination of alpha-fluoro-beta- alanine and 5-fluorouracil in plasma. J Chromatogr B Biomed Sci Appl 688:87-93
11. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476-87
12. The Meta-analysis Group in Cancer (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22:3766-3775
13. Mackean M, Planting A, Twelves C et al. (1998) Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced or metastatic cancer. J Clin Oncol 16:2977-2985
14. Budman DR, Meropol NJ, Reigner B et al. (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate, capecitabine. J Clin Oncol 16:1795-1802
15. Tebbutt NC, Norman AR, Cunningham D, Allen M, Chau I et al. (2003) Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. Br J Cancer 88:1510-1515
16. Ishikawa T, Utoh M, Sawada N et al. (1998) Tumour selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097
17. Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85-104
18. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, et al. (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349-358
19. Pentheroudakis G, Twelves C (2002) Capecitabine (Xeloda): from the laboratory to the patient's home. Clin Colorectal Cancer 2:16-23
20. Pinedo HM, Peters GFJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653-1664
21. Gieschke R, Reigner B, Blesch KS, Steimer JL (2002) Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodynam 29:25-47
22. Ngan SY, Michael M, Mackay J et al. (2004) A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 91:1019-1024
23. Machiels JPP, Duck L, Honhon B et al. (2005) Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: The RadioOxCape study. Proc Am Soc Clin Oncol GI (abstr 245)